AKT1 and osteosarcoma: In summary, this study identified candidate compounds with inhibitory effects on AKT1 through a series of screening procedures, paving the way for clinical pharmacotherapy studies of AKT1 inhibitory drugs (such as the treatment of ovarian, lung, osteosarcoma, and pancreatic cancers).